How Graft Handling and Conditioning Choices Shape Stem Cell Transplant Success

New data compare frozen donor cells, selective removal of immune cells, and refined conditioning scores. The studies show each tweak can change how quickly patients recover, how fully donor cells take over, and how long they survive after a transplant.

Key takeaways

• Cryopreserved (frozen) grafts lower the chance of full donor chimerism by day 60, but do not clearly affect relapse or overall survival in reduced‑intensity transplants [1].
• Removing T‑cell receptors αβ and CD19 from haploidentical grafts improves five‑year overall survival compared with T‑replete grafts plus post‑transplant cyclophosphamide, especially in children under two years old [2].
• Using the Transplant Conditioning Intensity (TCI) score to tailor chemotherapy before cord‑blood transplants can lower relapse in middle‑aged patients with myelodysplastic syndrome, though higher scores may raise overall mortality in older groups [3].

Frozen grafts: a modest trade‑off

A recent analysis of unrelated donor transplants that used reduced‑intensity conditioning (milder chemotherapy) and anti‑thymocyte globulin (ATG) to prevent graft‑versus‑host disease (GVHD) compared fresh versus cryopreserved stem cell products. The study found that only 33.8 % of patients receiving frozen grafts achieved full donor chimerism (≥95 % donor cells in both blood lineages) by day 60, versus 54.4 % with fresh grafts (p = 0.03) [1].

Full donor chimerism means the recipient’s blood is almost entirely made up of donor‑derived cells, a sign of successful engraftment. The lower rate with frozen grafts was linked to modestly lower early donor CD3⁺ (T‑cell) chimerism and a slight delay in engraftment. However, the same analysis showed no clear difference in relapse rates, overall survival (OS), progression‑free survival (PFS), or GVHD‑free, relapse‑free survival (GRFS) between the two groups [1].

These findings suggest that while freezing cells may slow early immune reconstitution, it does not appear to compromise long‑term disease control or survival in this specific setting. Larger prospective studies are still needed to confirm whether the chimerism gap translates into clinical consequences for other transplant protocols.

Selective graft depletion: better outcomes for young patients

In a retrospective Indian cohort of children with inborn errors of immunity (genetic immune disorders), researchers compared two haploidentical transplant approaches. One group received grafts depleted of T‑cell receptor αβ (TCRαβ) and CD19 (a B‑cell marker), while the other received T‑replete grafts followed by post‑transplant cyclophosphamide (PTCY) to control GVHD.

Five‑year overall survival was 62 % (95 % CI 48 %–73 %) in the TCRαβ/CD19‑depleted cohort versus 54 % (95 % CI 48 %–73 %) in the PTCY cohort [2]. The advantage was even larger in children younger than two years: 60 % survival with depletion versus 37 % with PTCY (p = 0.001) [2].

Engraftment rates, acute GVHD incidence, and chronic GVHD rates were similar between groups, but viral reactivations remained a challenge across both strategies. The authors noted that adding letermovir (an antiviral drug) prophylaxis and memory‑cell “add‑back” could further improve outcomes, though these ideas need formal testing.

The data imply that selectively removing the most reactive T‑cells and B‑cells from the donor product may reduce early immune complications while preserving the graft’s ability to reconstitute the immune system, especially in very young patients.

Conditioning intensity scores guide cord‑blood transplants

Cord‑blood transplantation (CBT) offers an alternative donor source for patients with myelodysplastic syndrome (MDS), a bone‑marrow disorder. A nationwide registry examined 1,127 adults who underwent CBT between 2008 and 2022, assigning each a Transplant Conditioning Intensity (TCI) score that reflects the strength of the chemotherapy and radiation given before infusion.

Patients were grouped by TCI scores of 3.5–4.0 (middle intensity) versus 4.5–5.0 (higher intensity). In the “Middle” age group (45–64 years), a higher TCI score (4.5–5.0) lowered the relapse incidence (HR 0.64, 95 % CI 0.45‑0.91, p = 0.014) but did not change overall mortality compared with the lower score (HR 1.61, 95 % CI 1.02‑2.49, p = 0.032) [3]. In younger patients (<45 years), no significant differences in mortality, relapse, or non‑relapse mortality were observed across scores [3].

These results suggest that intensifying conditioning may better eradicate residual disease in middle‑aged patients, but the benefit must be weighed against a higher risk of treatment‑related death in older adults. The TCI score thus provides a practical framework to tailor conditioning regimens based on patient age and disease risk.

Why these nuances matter

Engraftment speed, donor chimerism, and survival are interrelated milestones after hematopoietic stem cell transplantation (HSCT). A slower engraftment or lower chimerism can leave patients vulnerable to infections and disease recurrence, while overly aggressive conditioning can increase organ toxicity and non‑relapse mortality.

The three studies collectively illustrate that small technical choices—freezing the graft, depleting specific immune cells, or adjusting conditioning intensity—can shift these milestones. Cryopreservation appears safe overall but may require closer monitoring of early chimerism. Selective depletion offers a survival edge in very young children with immune defects, yet viral infections remain a hurdle. Conditioning scores help clinicians balance disease control against treatment‑related risks, especially in middle‑aged patients receiving cord blood.

Looking ahead

Future trials should prospectively test whether the day‑60 chimerism gap seen with frozen grafts translates into longer‑term complications. Larger, randomized studies of TCRαβ/CD19 depletion versus PTCY could clarify the best strategy for different age groups and disease types. Finally, integrating TCI scores with newer agents—such as targeted therapies or reduced‑toxicity radiation—may refine conditioning further, improving outcomes without adding excess risk.

For patients and families facing HSCT, these findings underscore that transplant success depends not only on donor match but also on how the graft is handled and how pre‑transplant conditioning is calibrated. Ongoing research will continue to fine‑tune these variables, aiming for faster recovery, stronger donor takeover, and longer, healthier lives.